J&J to Sell Remaining Stake in Kenvue Spinoff
By Dean Seal
Johnson & Johnson plans to unload its remaining 9.5% stake in Kenvue in a public offering set about a year after it started splitting off the Tylenol and Benadryl maker.
Kenvue said Monday that it will launch a secondary underwritten offering for 182.3 million shares that Johnson & Johnson is providing in a debt-for-equity exchange with Goldman Sachs and JP Morgan.
If sold at Friday's closing price of $20.54, the offering would fetch around $3.75 billion.
Kenvue said that Johnson & Johnson will no longer own any of its stock once the offering is completed.
Johnson & Johnson held an initial public offering for Kenvue a year ago and then sold most of its shares in the company in August.
The healthcare giant previously said it wanted to untangle the consumer-health unit's finances and operations from its prescription-drugs and medical device businesses. The effort followed similar moves by Pfizer and Merck, which sold their consumer-health businesses.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 13, 2024 10:06 ET (14:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Broadcom Stock a Buy, a Sell, or Fairly Valued?
-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Micron Stock Soars With the AI Boom—Is It a Buy or a Sell?
-
With a 4% Dividend Yield and Significant Growth Potential, This Stock Is a Buy
-
10 Stocks the Best Fund Managers Have Been Buying
-
GE Aerospace Stock Has Skyrocketed 86%. Is It a Buy?
-
2 Undervalued Dividend Stocks the Best Managers Are Buying
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains